A trio of CAR T updates: Clinical Report 

In a week with only one stock-moving clinical development, Sarepta’s confirmatory trial miss in Duchenne muscular dystrophy, a trio of CAR T cell therapies made quiet progress in refractory populations. Two of these were in cancer indications and one in an autoimmune setting.

Caribou Biosciences Inc. (NASDAQ:CRBU) reported data from two Phase I trials, ANTLER and CaMMouflage, testing allogeneic CAR T therapies in patients with relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, respectively...